不同活检指征下PIRADS评分对MR靶向活检检出率的评估
该回顾性研究纳入2014至2017年单中心255例接受超声-MR融合活检的男性(共365个病灶),按活检初治、既往TRUS活检阴性或主动监测分组,分析PIRADS评分与任何前列腺癌及临床显著癌(Gleason≥3+4)检出的相关性。结果显示PIRADS评分与癌检出率显著相关,且不同活检指征下检出率存在差异,既往阴性活检者PIRADS 3和4病灶的检出率较低。
要点
- PIRADS评分与任何及临床显著前列腺癌检出率显著相关。
- 不同活检指征下活检检出率不同,选择活检阈值时应考虑临床病史。
- 既往TRUS活检阴性者PIRADS 3病灶可考虑避免活检。
核心结论
- 癌检出率与PIRADS评分显著相关,且不同活检指征下活检检出率存在差异。
研究设计与样本
- 回顾性研究纳入2014至2017年单中心连续接受超声-MR融合活检的255例男性,共365个病灶。
- 按临床病史分为活检初治、既往TRUS活检阴性或主动监测三组。
主要发现
- PIRADS 1-2、3、4、5病灶的任何前列腺癌检出率分别为7.7%、29.7%、42.3%、82.4%。
- PIRADS 1-2、3、4、5病灶的临床显著癌检出率分别为0%、8.9%、21.4%、62.7%。
- 任何癌和显著癌诊断的ROC曲线下面积分别为0.69(95%CI: 0.64-0.74)和0.74(95%CI: 0.69-0.79)。
- 既往活检阴性者PIRADS 3和4病灶的任何前列腺癌检出率低于活检初治或主动监测者。
临床怎么用
- 选择活检PIRADS阈值时应结合患者既往活检史等临床指征。
- 对既往TRUS活检阴性男性,PIRADS 3病灶可考虑避免活检。
局限性
- 回顾性单中心研究,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Magnetic resonance imaging is being widely adopted in the clinical management of prostate cancer. The correlation of the Prostate Imaging Reporting and Data System (PIRADS) to the presence of cancer has been established but studies have primarily evaluated this in a single clinical setting. This study aims to characterize the correlation of PIRADS score to the diagnosis of cancer on fusion biopsy among men who are undergoing primary biopsy, those who have had a previous negative biopsy or men on active surveillance. MATERIALS & METHODS: A consecutive sample of men undergoing US-MR biopsy at a single academic institution from 2014 to 2017 were included in this retrospective study. Men were stratified into groups according to their clinical history: biopsy-naïve, previous negative transrectal ultrasound (TRUS) biopsy or on active surveillance. The correlation of PIRADS score to the diagnosis of any and clinically significant cancer (Gleason score ≥ 3 + 4) was determined. RESULTS: A total of 255 patients with 365 discrete lesions were analyzed. PIRADS score 1-2, 3, 4 and 5 yielded any prostate cancer in 7.7, 29.7, 42.3 and 82.4% of the cases, respectively, across all indications while clinically significant cancer was found in 0, 8.9, 21.4 and 62.7%, respectively. The area under the receiver operative curves for the diagnosis of any and significant cancer was 0.69 (95%CI: 0.64-0.74) and 0.74 (95%CI: 0.69-0.79) respectively. Men who have had a previous negative biopsy had lower detection rates for any prostate cancer for PIRADS 3 and 4 lesions compared to those that were biopsy-naïve or on active surveillance. CONCLUSION: Cancer detection rates are significantly associated with PIRADS score. Biopsy yields differ across biopsy indications which should be considered when selecting a PIRADS score threshold for biopsy. Biopsy of PIRADS 3 lesions could potentially be avoided in men who have previously undergone a negative TRUS biopsy.
引用
- Sathianathen NJ, Konety BR, Soubra A, et al. Which scores need a core? An evaluation of MR-targeted biopsy yield by PIRADS score across different biopsy indications. Prostate Cancer Prostatic Dis. 2018. PMID: 30038389. doi:10.1038/s41391-018-0065-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。